3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
8
Breast Neoplasms
7
Urinary Bladder Neoplasms
4
Carcinoma, Transitional Cell
4
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Prostatic Neoplasms, Castration-Resistant
1
Pancreatic Neoplasms
1
Meningeal Carcinomatosis
1
HRD Cancer
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Advanced Breast Cancer
1
Interventions
sacituzumab govitecan
1
eribulin
1
balixafortide
1
Taxes
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Advanced Breast Cancer
×
sacituzumab govitecan
×
Clear all
NCT06612203
2025-12-05
WIN-B
MedSIR
Phase 1/2
Active not recruiting
76 enrolled